CD24 and myeloid sarcoma: In this model, meta-analysis demonstrated a significant association between the CD24 Ala57Val polymorphism and MS risk in all study subjects (OR = 2.28, 95% CI: 1.68–3.10, Pz < 0.001) (Table 2 and Fig. 2).